Compare Macy's Inc (M) vs Natera Inc. Common Stock (NTRA) Price & Performance

Macy's (M) trades at $22.68, down 1.35% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company shows improving fundamentals with Q2 2026 earnings beating estimates and raised full-year guidance, supported by a 'Bold New Chapter' strategy driving digital and omnichannel growth. Valuation ratios remain attractive with a P/E of 8.33 and P/S of 0.27, while cash flow trends have strengthened with net cash flow turning positive in 2025.

The outlook is cautiously optimistic given low valuations and strategic initiatives, but risks include competitive pressures, uneven second-half growth expectations, and macroeconomic sensitivity. Analyst consensus is mixed with a $24.25 price target, implying modest upside, though the stock's 3.5% dividend yield adds income appeal for patient investors amid execution risks.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.